Top Qs
Timeline
Chat
Perspective
JPC0323
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
JPC0323, also known as N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide, is a dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator related to oleamide.[1][2] It showed negligible affinity for roughly 50 other targets and did not bind to the orthosteric sites of these receptors.[1][2] The drug does not affect the serotonin 5-HT2B receptor.[1][2]
JPC0323 showed favorable pharmacokinetic properties in preclinical research.[1][2] It produced hypolocomotion in a serotonin 5-HT2C receptor-dependent but not serotonin 5-HT2A receptor-dependent manner in rats, suggesting that it might be a preferential serotonin 5-HT2C receptor positive allosteric modulator in vivo.[1][2] The drug was not assessed in terms of head-twitch response, an animal behavioral proxy of psychedelic effects.[2] It is unknown whether it might have hallucinogenic effects via serotonin 5-HT2A receptor potentiation, but its developers speculated that it might have reduced potential in this regard compared to orthosteric agonists.[2]
JPC0323 was derived as an analogue of the fatty acid amide oleamide and was first described in the scientific literature by 2023.[1][2] It was described as a "first-in-class" dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator.[2]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads